Yahoo Web Search

Search results

1. • Vinva Investment Management Ltd Sells 681 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

     ETF DAILY NEWS· 2 days ago

     Vinva Investment Management Ltd lessened its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 28.6% in the fourth quarter, HoldingsChannel.com reports. The fund ...

2. • 

     New cancer treatment increases efficacy by injecting chemo directly into tumor cells

     BGR· 2 days ago

     Chemotherapy has proven to be a fairly successful treatment for cancer. The Food and Drug...

3. • 

     ComboMATCH Precision Medicine Cancer Trials

     National Cancer Institute· 7 days ago

     ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a group of precision medicine cancer clinical trials,...

4. • 

     Bio-Path secures $4 million in private placement By Investing.com

     Investing.com· 7 days ago

     Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology firm, announced today it has entered into a...

5. • FDA Approves Imetelstat for Rare Low-Risk Blood Cancer

     Medscape· 4 days ago

     The approval for the first-in-class agent is "potentially practice changing" given the lack of treatment options for transfusion-dependent lower-risk MDS patients.

6. • 

     The Big Climb

     The Bradford Era· 4 days ago

     As a geezer who can barely make it up the dozen steps in my house without getting winded, I never thought I would make it up and down 2,500 steps

7. • Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Up 4.3%

     ETF DAILY NEWS· 2 days ago

     Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) was up 4.3% during trading on Friday . Needham & Company LLC reissued a “buy” rating and issued a $222.00 price objective on shares of ...

8. • AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

     Zacks· 4 days ago

     Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.

9. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 6 days ago

     Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% PR Newswire SUZHOU, China and ROCKVILLE, Md., June 4, 2024 SUZHOU, China ...

10. • Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $32.00 Consensus Price Target from Brokerages

      ETF DAILY NEWS· 3 days ago

      Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the company, Marketbeat ...